{
    "clinical_study": {
        "@rank": "56837", 
        "acronym": "TOX", 
        "arm_group": {
            "arm_group_label": "Pathological Response", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Early stage diagnosis of gastric cancer has ensued different approaches in its resection\n      strategies. In order to increase the proportion of cases that undergo radical resection and\n      reduce the recurrence rate, different pre-operative treatments are introduced. Here, the\n      investigators investigate an active preoperative chemotherapeutic regimen to in patients\n      with locally advanced gastric cancer."
        }, 
        "brief_title": "Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma", 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Tissue diagnosis of gastric or gastroesophageaql junction Adenocarcinoma\n\n          -  T3, T4 any N with non metastatic condition\n\n          -  Age 18 - 70 years\n\n          -  Performance status 0,1 according to ECOG criteria\n\n          -  Adequate bone marrow , liver and renal function\n\n          -  Hemoglobin \u2265 11 g/dl\n\n          -  Platelets \u2265 100000 / mm3\n\n          -  Absolute Neutrophil Count \u2265 1500/mm3\n\n          -  Normal Bilirubin\n\n          -  Normal Transaminases\n\n          -  Normal creatinin\n\n          -  Absence of active co-morbid illness (uncontrolled infection, uncontrolled DM,\n             cardiopulmonary disease)\n\n        Exclusion Criteria:\n\n          -  Any metastatic disease, T1, T2, N0"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672333", 
            "org_study_id": "TOX protocol"
        }, 
        "intervention": {
            "arm_group_label": "Pathological Response", 
            "description": "oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days", 
            "intervention_name": "TOX", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Fayyazbakhsh hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Response Rate and Side Effects of Preoperative Chemotherapy With Docetaxel, Oxaliplatin and Capcitabine (TOX) in Patients With Locally Advanced Operable Gastric Adenocarcinoma", 
        "overall_official": {
            "affiliation": "Milad Hospital", 
            "last_name": "Bahram Salmanian, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A single expert pathologist evaluates the pathologic outcome of the chemotherapy regimen after the completion of courses. Participants are divided into 3 groups including complete pathologic response, partial pathologic response and pathologic stable disease.", 
            "measure": "Pathologic Response rate", 
            "safety_issue": "No", 
            "time_frame": "Participants are assessed after 4 chemotherapy courses 3 weeks apart, an expected period of 12 weeks from starting the study treatment protocol."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672333"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Milad Hospital", 
            "investigator_full_name": "Dr Seyed-Hossein Yahyazadeh-Jabari", 
            "investigator_title": "Director of Clinical Research Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "A single expert clinician evaluates the clinical outcome of the chemotherapy regimen after 2 primary courses 3 weeks apart. Evaluation is done with regards to the \"TNM\" scoring of gastric cancer (T for the size and expansion of the tumor, N for lymph node involvement, M for distant metastasis). Participants are divided into 4 groups including clinically progressive disease, complete clinical response, partial clinical response and clinically stable disease.", 
            "measure": "clinical Response rate", 
            "safety_issue": "Yes", 
            "time_frame": "Participants are assessed after 2 courses of Chemotherapy 3 weeks apart, an expected period of 6 weeks from starting the study treatment protocol."
        }, 
        "source": "Milad Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Milad Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}